Literature DB >> 21741501

Genotype-phenotype correlation in 13q13.3-q21.3 deletion.

Lucie Tosca1, Sophie Brisset, François M Petit, Corinne Metay, Stéphanie Latour, Benoît Lautier, Axel Lebas, Luc Druart, Olivier Picone, Anne-Elisabeth Mas, Sophie Prévot, Marc Tardieu, Michel Goossens, Gérard Tachdjian.   

Abstract

Pure interstitial deletions of the long arm of chromosome 13 are correlated with variable phenotypes according to the size and the location of the deleted region. Deletions involving the 13q13q21 region are rare. In order to establish interstitial 13q genotype-phenotype correlation, we used high resolution 244K oligonucleotide array in addition to conventional karyotype and molecular (fluorescent in situ hybridization, microsatellite markers analysis) techniques in two independent probands carrying a deletion 13q13 to 13q21. First patient was a 3-year-old girl with mental retardation and dysmorphy carrying a 13q13.3q21.31 de novo deletion diagnosed post-natally. The second one was a fetus with de novo del(13)(q14q21.2) associated with first trimester increased nuchal translucency. We showed that specific dysmorphic features (macrocephaly, high forehead, hypertelorism, large nose, large and malformed ears and retrognathia) were correlated to the common 13q14q21 chromosomal segment. Physical examination revealed overgrowth with global measurement up to the 95th percentile in both probands. This is the second description of overgrowth in patients carrying a 13q deletion. Haploinsufficiency of common candidates genes such as CKAP2, SUGT1, LECT1, DCLK1 and SMAD9, involved in cell division and bone development, is a possible mechanism that could explain overgrowth in both patients. This study underlines also that cytogenetic analysis could be performed in patients with overgrowth.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741501     DOI: 10.1016/j.ejmg.2011.06.004

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

Review 1.  A Clinical Review of Generalized Overgrowth Syndromes in the Era of Massively Parallel Sequencing.

Authors:  Benjamin Kamien; Anne Ronan; Gemma Poke; Ingrid Sinnerbrink; Gareth Baynam; Michelle Ward; William T Gibson; Tracy Dudding-Byth; Rodney J Scott
Journal:  Mol Syndromol       Date:  2018-01-25

2.  13q deletion syndrome resulting from balanced chromosomal rearrangement in father: the significance of parental karyotyping.

Authors:  Petra Ketteler; Deniz Kanber; Sabine Dittner-Moormann; Madlen Reschke; Eva Biewald; Alma Kuechler; Barbara Klein; Beate Timmermann; Dietmar Lohmann
Journal:  Mol Cytogenet       Date:  2020-07-23       Impact factor: 2.009

3.  A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD-Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis.

Authors:  Celia L Gregson; Dylan J M Bergen; Paul Leo; Richard B Sessions; Lawrie Wheeler; April Hartley; Scott Youlten; Peter I Croucher; Aideen M McInerney-Leo; William Fraser; Jonathan Cy Tang; Lisa Anderson; Mhairi Marshall; Leon Sergot; Lavinia Paternoster; George Davey Smith; Matthew A Brown; Chrissy Hammond; John P Kemp; Jon H Tobias; Emma L Duncan
Journal:  J Bone Miner Res       Date:  2019-11-14       Impact factor: 6.390

4.  De novo 13q13.3-21.31 deletion involving RB1 gene in a patient with hemangioendothelioma of the liver.

Authors:  Novella Rapini; Roberta Lidano; Silvia Pietrosanti; Giuseppina Vitiello; Chiara Grimaldi; Diana Postorivo; Anna Maria Nardone; Francesca Del Bufalo; Francesco Brancati; Maria Luisa Manca Bitti
Journal:  Ital J Pediatr       Date:  2014-01-16       Impact factor: 2.638

5.  13q mosaic deletion including RB1 associated to mild phenotype and no cancer outcome - case report and review of the literature.

Authors:  Ilaria Bestetti; Alessandra Sironi; Ilaria Catusi; Milena Mariani; Daniela Giardino; Siranoush Manoukian; Donatella Milani; Lidia Larizza; Chiara Castronovo; Palma Finelli
Journal:  Mol Cytogenet       Date:  2018-09-19       Impact factor: 2.009

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.